TTR and cardiomyopathy: There have been advances in the effective treatment of TTR amyloidosis with the regulatory agency approvals of the TTR stabilizer, tafamidis; approved in the early 2010s for TTR familial polyneuropathy and, the late 2010s for TTR cardiomyopathy [8].